A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza¿) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Canc

Administered By

Awarded By

Contributors

Start/End

  • February 13, 2018 - February 29, 2020